<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04776486</url>
  </required_header>
  <id_info>
    <org_study_id>APHP190414</org_study_id>
    <secondary_id>2019-A00654-53</secondary_id>
    <nct_id>NCT04776486</nct_id>
  </id_info>
  <brief_title>Iohexol Clearance in Critically Ill Patients With Augmented Renal Creatinine Clearance</brief_title>
  <acronym>GFR-ARC</acronym>
  <official_title>Evaluation of Glomerular Filtration Rate Using Iohexol Plasma Clearance in Critically Ill Patients With Augmented Renal Creatinine Clearance</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluation of glomerular filtration rate using iohexol plasma clearance in critically ill&#xD;
      patients with augmented renal creatinine clearance&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Single center study in ICU patients with augmented renal clearance comparing glomerular&#xD;
      filtration rate (GFR) as measured by iohexol plasma clearance to that measured by creatinine&#xD;
      clearance. Primary objective is to compare the GFR estimates made by iohexol plasma clearance&#xD;
      (as reference method) and creatinine clearance using Bland-Altman method.&#xD;
&#xD;
      Secondary objective are to compare GFR as measured by iohexol plasma clearance to that&#xD;
      calculated with the most commonly used renal clearance estimating formulas (Cockcroft and&#xD;
      Gault, MDRD and CKD-EPI ), evaluate clinical determinant of the observed differences and&#xD;
      evaluate determinants of extracellular volume.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 3, 2020</start_date>
  <completion_date type="Anticipated">September 2023</completion_date>
  <primary_completion_date type="Anticipated">March 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>GFR obtained by the iohexol clearance technique</measure>
    <time_frame>6 hours</time_frame>
    <description>GFR as measured by iohexol plasma clearance to evaluate its concordance, by the Bland and Altman method, with that obtained by measuring the clearance of creatinine.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>GFR obtained by the creatinine clearance technique</measure>
    <time_frame>6 hours</time_frame>
    <description>GFR as measured by creatinine plasma clearance</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>GFR calculated using the Cockroft-Gault equation</measure>
    <time_frame>6 hours</time_frame>
    <description>Estimation of GFR using the Cockroft-Gault method based on the serum creatinine clearance measured on the day of intervention and the patient's weight of the day, and the agreement with the GFR measured by the iohexol clearance</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GFR calculated using the Modification of diet in renal disease (MDRD) formula</measure>
    <time_frame>6 hours</time_frame>
    <description>Estimation of GFR using MDRD method based on the serum creatinine clearance measured on the day of intervention and the patient's weight of the day, and the agreement with the GFR measured by the iohexol clearance</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GFR calculated using the Chronic Kidney Disease - Epidemiology Collaboration (CKD-EPI) equation</measure>
    <time_frame>6 hours</time_frame>
    <description>Estimation of GFR using CKD-EPI method based on the serum creatinine clearance measured on the day of intervention and the patient's weight of the day, and the agreement with the GFR measured by the iohexol clearance</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasmatic Levetiracetam dosing</measure>
    <time_frame>6 hours</time_frame>
    <description>To detect underdosing and risk of therapeutic failure of Levetiracetam</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasmatic Vancomycin dosing</measure>
    <time_frame>6 hours</time_frame>
    <description>To detect underdosing and risk of therapeutic failure of Vancomycin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasmatic Piperacillin dosing</measure>
    <time_frame>6 hours</time_frame>
    <description>To detect underdosing and risk of therapeutic failure of Piperacillin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasmatic Cefotaxim dosing</measure>
    <time_frame>6 hours</time_frame>
    <description>To detect underdosing and risk of therapeutic failure of Cefotaxim</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasmatic Aminoglycoside dosing</measure>
    <time_frame>6 hours</time_frame>
    <description>To detect underdosing and risk of therapeutic failure of Aminoglycoside</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Augmented Renal Clearance</condition>
  <condition>Critically Ill</condition>
  <arm_group>
    <arm_group_label>Critically ill patients with augmented renal clearance</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ICU patients with estimated renal clearance over 130ml/min/1.73m2</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Iohexol</intervention_name>
    <description>Intravenous injection of 5 ml of iohexol (Omnipaque) to calculate the glomerular filtration rate (area under the curve).&#xD;
Blood samples (2 ml) and urine (2 ml minimum) are to be collected for the determination of iohexol clearance at the following time points: pre-dose, 5 minutes, and 1, 2, 3, 4, 5, 6 hours post dose.</description>
    <arm_group_label>Critically ill patients with augmented renal clearance</arm_group_label>
    <other_name>Omnipaque</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  ICU patient&#xD;
&#xD;
          -  24h Creatinine clearance &gt;130ml/min/1.73m2&#xD;
&#xD;
          -  Urinary catheterization&#xD;
&#xD;
          -  Affiliation to a social security scheme&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  CT-scan with contrast media infusion the day of inclusion&#xD;
&#xD;
          -  Documented allergy to contrast media&#xD;
&#xD;
          -  Patient under guardianship / curatorship&#xD;
&#xD;
          -  Patient benefiting from the &quot;State Medical Assistance&quot;&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Benjamin G Chousterman, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Lariboisière Hospital, APHP Nord</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Magalie Collet, MD</last_name>
    <phone>+33 (0)149958515</phone>
    <email>magalie.collet@aphp.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Lariboisière Hospital, Surgical ICU</name>
      <address>
        <city>Paris</city>
        <state>Ile De France</state>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Magalie Collet, MD</last_name>
      <phone>+33 (0)149958515</phone>
      <email>magalie.collet@aphp.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Salmon-Gandonnière C, Benz-de Bretagne I, Mercier E, Joret A, Halimi JM, Ehrmann S, Barin-Le Guellec C. Iohexol clearance in unstable critically ill patients: a tool to assess glomerular filtration rate. Clin Chem Lab Med. 2016 Nov 1;54(11):1777-1786. doi: 10.1515/cclm-2015-1202.</citation>
    <PMID>27166722</PMID>
  </reference>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>July 17, 2020</study_first_submitted>
  <study_first_submitted_qc>February 26, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 1, 2021</study_first_posted>
  <last_update_submitted>March 19, 2021</last_update_submitted>
  <last_update_submitted_qc>March 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Iohexol</keyword>
  <keyword>Augmented renal clearance</keyword>
  <keyword>Intensive Care Unit</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Critical Illness</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

